Abstract
Irinotecan is an active cytotoxic agent for various cancers, and is converted to SN‐38, its most active metabolite, by carboxy‐lesterase converting enzyme (CCE) in vivo. Although the primary metabolic site is in the liver, ex vivo studies have proven that irinotecan is also converted to SN‐38 in intestines, plasma and tumor tissues. The present study attempted to elucidate the in vitro conversion efficiency in human plasma, and to examine possible inter‐individual variability and its clinical significance. Plasma samples were taken from 57 patients with lung cancer, 3 patients with benign pulmonary diseases and 9 healthy volunteers. After addition of 157 μM irinotecan to plasma, time courses of SN‐38 concentration, measured by high‐performance liquid chromatog‐raphy (HPLC), were investigated. All subjects showed linear increase in SN‐38 concentration during the first 60‐min period, followed by a plateau. Mean and standard deviation of the conversion rate in the first 60 min were 515.9±50.1 pmol/ml/h (n=69), with a coefficient of variation of 0.097. Although most of the subjects showed comparable conversion rates, 3 subjects had significantly higher conversion rates. In conclusion, the results of this study suggest that the enzyme activity of CCE in human plasma may show inter‐individual variability.
References
- 1. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CFT‐11 hydrolysis by human liver carboxylesterase isoforms hCE‐1 and hCE‐2. Cancer Res 2000; 60: 1189–92. [PubMed] [Google Scholar]
- 2. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N. Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990; 5O: 5919–24. [PubMed] [Google Scholar]
- 3. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN‐38, a metabolite of the camptothecin derivative CFT‐11, in the antitumor effect of CFT‐11. Cancer Res 1991; 51: 4187–91. [PubMed] [Google Scholar]
- 4. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (cpt‐11). Clin Cancer Res 2001; 7: 2182–94. [PubMed] [Google Scholar]
- 5. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N. A pharmacokinetic and pharmacodynamic analysis of CFT‐11 and its active metabolite SN‐38. Jpn J Cancer Res 1995; 86: 101–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small‐cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068–74. [DOI] [PubMed] [Google Scholar]
- 7. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12. [DOI] [PubMed] [Google Scholar]
- 8. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T. Phase I study of weekly intravenous infusions of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer. J Natl Cancer Inst 1991; 83: 1164–8. [DOI] [PubMed] [Google Scholar]
- 9. Rivory LP. Metabolism of CPT‐11. Impact on activity. Ann N Y Acad Sci 2000; 922: 205–15. [DOI] [PubMed] [Google Scholar]
- 10. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function [comment]. J Clin Oncol 1989; 7: 1748–56. [DOI] [PubMed] [Google Scholar]
- 11. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN‐38, the active metabolite of irinotecan. Ann Oncol 1998;9: 845–7. [DOI] [PubMed] [Google Scholar]
- 12. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP‐glucuronosyltrans‐ferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921–6. [PubMed] [Google Scholar]
- 13. Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, Gupta E. In vitro activation of irinotecan to SN‐38 by human liver and intestine. Anticancer Res 1999; 19: 2067–71. [PubMed] [Google Scholar]
- 14. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R, Canal P. CPT‐11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999; 80: 364–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Guemei AA, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov MV, Grem JL, Ismail AS, Bowen D, Taylor RE, Takimoto CH. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN‐38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chem.other Pharmacol 2001; 47: 283–90. [DOI] [PubMed] [Google Scholar]
- 16. Atsumi R, Okazaki O, Hakusui H. Metabolism of irinotecan to SN‐38 in a tissue‐isolated tumor model. Biol Pharm. Bull 1995; 18: 1024–6. [DOI] [PubMed] [Google Scholar]
- 17. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT‐11) to its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin (SN‐38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52: 1103–11. [DOI] [PubMed] [Google Scholar]
- 18. Haaz MC, Rivory LP, Riche C, Robert J. The transformation of irinotecan (CPT‐11) to its active metabolite SN‐38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 257–62. [DOI] [PubMed] [Google Scholar]
- 19. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN‐38. Cancer Chemother Pharmacol 1995; 36: 463–72. [DOI] [PubMed] [Google Scholar]
- 20. Morton CL, Wadkins RM, Banks MK, Potter PM. The anticancer prodrug CPT‐11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN‐38 by butyrylcholinesterase. Cancer Res 1999; 59: 1458–63. [PubMed] [Google Scholar]
- 21. Hosokawa M, Endo T, Fujisawa M, Kara S, Iwata N, Sato Y, Satoh T. Inter‐individual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 1995; 23: 1022–7. [PubMed] [Google Scholar]